KN046 in Subjects With Advanced Pancreatic Ductal Adenocarcinoma.
Status:
Not yet recruiting
Trial end date:
2024-08-30
Target enrollment:
Participant gender:
Summary
This study is a multicenter, randomized, double-Blind Phase III Study to compare the clinical
efficacy and safety of KN046 plus gemcitabine and nab-paclitaxel versus placebo plus
gemcitabine and nab-paclitaxel in subjects with advanced pancreatic ductal adenocarcinoma who
have not previously received systemic treatment.